Bond University Researchers Trial Stem Cell Therapy to Restore Vision in Animals
Key Insights
Researchers at Bond University (search) are trialing stem cell (search) therapies in pigs to treat blindness, specifically targeting age-related macular degeneration (search) and retinitis pigmentosa (search).
The stem cell (search) technology aims to efficiently create cells needed for vision restoration, potentially lowering production costs and increasing accessibility for patients.
Animal studies involving retinal cell transplantation into blind pigs are planned to assess the treatment's efficacy and safety over approximately 18 months.
A team at Bond University (search) is currently testing a stem cell (search) therapy aimed at curing blindness, initially in pigs, with the ultimate goal of treating age-related macular degeneration (search) and retinitis pigmentosa (search) in humans. Led by Dr. Jason Limnios at the Clem Jones Centre for Regenerative Medicine (search) (CJCRM), the research focuses on developing efficient stem cell technologies to restore vision.
Advancing Stem Cell Therapies for Vision Loss
Dr. Limnios emphasized the advancements made over the past decade in creating cells necessary for vision restoration. "Over the past decade we've developed fast and efficient ways to create the cells needed to save and restore vision in patients," he stated. This progress aims to reduce production costs, making therapies more accessible. However, Dr. Limnios also noted the significant steps required between laboratory breakthroughs and approved human therapies.
Preclinical Studies in Animal Models
The CJCRM is planning comprehensive studies in both small and large animals to thoroughly evaluate the treatment's effectiveness and safety profile. "We're working with facilities in Queensland to set up the animal studies where we will transplant new retinal cells into the back of the eyes of blind animals," Dr. Limnios explained. The choice of pigs as a model is strategic due to the similarity between pig and human eyes, allowing the surgical team to refine the transplantation process. Initial results on the effectiveness of the cell transplants are expected approximately 18 months after the studies commence.
Collaborative Efforts and Future Directions
To further advance stem cell (search) therapies in Australia, the CJCRM is fostering a network of national and international collaborations. This includes partnerships with universities and industry stakeholders, jointly bidding for a Cooperative Research Centre (CRC). Securing a CRC would signify a strong commitment to developing cutting-edge technologies within Australia, preventing the need to seek resources and expertise overseas. Dr. Limnios noted the importance of this initiative: "This CRC will show that Australia is committed to becoming a serious player on the world stage," ultimately leading to improved health outcomes for Australians.